Targeting inflammation in lung transplant recipients with a new medication.
Targeting Inflammation and Alloimmunity in Lung Transplant Recipients With Clazakizumab
This study is looking at how a medication called Clazakizumab can help lung transplant patients by reducing inflammation and improving their chances of a successful recovery, so they can breathe easier and feel better in the long run.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10879069 on NIH RePORTER |
What this research studies
This research focuses on improving the survival rates of lung transplant recipients by targeting inflammation and immune responses that can lead to complications. The approach involves using a medication called Clazakizumab to inhibit a specific cytokine, IL-6, which is linked to harmful inflammatory processes. By blocking IL-6, the study aims to reduce the risk of acute rejection and chronic lung allograft dysfunction, potentially leading to better long-term outcomes for patients. Participants will be monitored for changes in immune responses and overall lung function.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recently undergone lung transplantation and are at risk for complications related to inflammation and immune response.
Not a fit: Patients who are not lung transplant recipients or those with contraindications to Clazakizumab may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and quality of life for lung transplant recipients.
How similar studies have performed: Previous studies have shown success with similar approaches in kidney transplant recipients, indicating potential for positive outcomes in lung transplantation as well.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Madsen, Joren C — Massachusetts General Hospital
- Study coordinator: Madsen, Joren C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.